Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Sees Generics Opportunity In Japan For Innovator Companies

This article was originally published in PharmAsia News

Executive Summary

A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito

You may also be interested in...



Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)

Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharma company, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.

Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)

Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharma company, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.

Eisai Plans R&D Revamp To Turn The Development Tide

Six autonomous product creation units to focus on neuroscience, oncology, antibodies and immunological anti-inflammatory diseases, with units also focused on late stage drugs and Japanese clinical research.

Related Content

UsernamePublicRestriction

Register

SC070847

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel